RyosukeTsugitomi· @Rtsugitom · X·· 2 天前评分70
正文 · 原文
Day 3 of #ESMO26 is about to begin!
Another exciting day ahead, packed with highly anticipated presentations, including KRASCENDO and SAFFRON!
0 赞 · 0 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org来源：RyosukeTsugitomi · x.com